Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Amortizatization of Intangibles (2017 - 2025)

Avalo Therapeutics (AVTX) has disclosed Amortizatization of Intangibles for 7 consecutive years, with $347000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Amortizatization of Intangibles changed N/A year-over-year to $347000.0, compared with a TTM value of $347000.0 through Sep 2025, changed N/A, and an annual FY2023 reading of $1.8 million, up 31.61% over the prior year.
  • Amortizatization of Intangibles was $347000.0 for Q3 2025 at Avalo Therapeutics, down from $900000.0 in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $900000.0 in Q3 2023 and bottomed at $104000.0 in Q2 2021.
  • Average Amortizatization of Intangibles over 4 years is $375363.6, with a median of $349000.0 recorded in 2021.
  • Peak annual rise in Amortizatization of Intangibles hit 223.08% in 2022, while the deepest fall reached 0.0% in 2022.
  • Year by year, Amortizatization of Intangibles stood at $349000.0 in 2021, then changed by 0.0% to $349000.0 in 2022, then surged by 157.88% to $900000.0 in 2023, then plummeted by 61.44% to $347000.0 in 2025.
  • Business Quant data shows Amortizatization of Intangibles for AVTX at $347000.0 in Q3 2025, $900000.0 in Q3 2023, and $349000.0 in Q2 2023.